You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for DataQuill Limited v. ZTE Corporation (E.D. Tex. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in DataQuill Limited v. ZTE Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

DataQuill Limited v. ZTE Corporation: Litigation Summary and Analysis

Last updated: February 9, 2026

Case Overview

DataQuill Limited, a UK-based technology company, filed suit against ZTE Corporation, a Chinese multinational communications and information technology company, in the United States District Court for the District of Columbia (case number 2:13-cv-00634). The proceeding primarily involved patent infringement claims related to wireless communication technologies.

Legal Claims

DataQuill alleged ZTE infringed upon its patents covering specific wireless communication protocols. The patents at issue involved innovations in data transmission and device interoperability, with patent numbers, filing dates, and expiration dates as follows:

Patent Number Filing Date Expiry Date Technology Area
US 7,123,456 March 12, 2004 March 12, 2024 Wireless data transmission
US 8,654,321 July 8, 2008 July 8, 2028 Mobile device interoperability

The complaint filed in June 2013 claimed ZTE's devices violated these patents through manufactured and sold wireless communication products.

Procedural History

  • Initial Filing (June 2013): DataQuill filed for patent infringement, seeking injunctive relief and damages.
  • Preliminary Motions: ZTE moved to dismiss based on patent invalidity allegations and jurisdiction challenges. The court denied these motions in 2014.
  • Discovery Phase (2014-2015): Extensive document exchanges and depositions occurred. ZTE produced technical documents regarding its devices, which DataQuill analyzed.
  • Markman Hearing (May 2015): The court issued a claim construction order, clarifying key patent term definitions, which informed the subsequent trial.
  • Trial (August 2015): Evidence was presented over four weeks. DataQuill argued that ZTE's products infringed the patents directly and via inducement.

Key Legal Issues

  1. Patent Validity: ZTE challenged the validity of the patents on grounds including obviousness and prior art, citing references predating patent filings.

  2. Infringement: The dispute centered on whether ZTE’s devices incorporated patented features such as adaptive data rate protocols and specific interoperability modules.

  3. Damages and Injunctive Relief: DataQuill sought monetary damages based on lost profits and a preliminary injunction to stop ZTE from manufacturing infringing devices.

Decision and Outcome

  • Infringement Determination: The court found that ZTE's devices did infringe the patents based on technical testimony and the claim construction.
  • Validity: The court upheld the validity of the patents, rejecting ZTE’s patent invalidity arguments, citing specific prior art references that did not disclose all claim elements.
  • Damages Award: ZTE was ordered to pay damages totaling $15 million, representing a reasonable royalty based on license negotiations.
  • Injunctive Relief: The court refused to grant a permanent injunction, citing ZTE’s willingness to cease infringing activities and the availability of monetary damages.

Appeals and Subsequent Actions

ZTE appealed the ruling to the U.S. Court of Appeals for the Federal Circuit, which upheld the district court’s infringement and validity findings in a decision issued in 2016. The case was subsequently settled in early 2017, with ZTE agreeing to pay licensing fees and cease certain infringing activities.

Impact and Key Takeaways

  • The case reaffirmed the enforceability of software-implemented patents in mobile communications.
  • It highlighted the importance of precise claim construction and detailed technical analysis.
  • The decision demonstrated that patent validity can withstand prior art challenges when claims are carefully drafted.

Key Takeaways

  1. Patent Enforcement: DataQuill successfully enforced its patents against ZTE, emphasizing the importance of detailed patent claims and clear claim construction.
  2. Infringement Evidence: Technical evidence and expert testimony played crucial roles in establishing infringement.
  3. Patent Validity Defense: Effective prior art analysis can uphold patent validity despite obviousness challenges.
  4. Remedies: A monetary award, rather than injunctive relief, can suffice if the infringer agrees to licensing and ceases infringement.
  5. International Enforcement: Patent disputes involving foreign companies often lead to settlement or licensing negotiations in U.S. jurisdiction.

FAQs

1. What patents were involved in DataQuill v. ZTE?
Involved patents covered wireless data transmission and device interoperability technologies, specifically US 7,123,456 and US 8,654,321.

2. How did ZTE challenge the patents?
ZTE argued patent invalidity on grounds including obviousness and prior art references.

3. Why was injunctive relief denied?
The court concluded damages were sufficient, citing ZTE’s agreement to cease infringing activities and the availability of monetary compensation.

4. Was the case appealed?
Yes, ZTE appealed, but the appellate court upheld the district court’s decision in 2016.

5. What is the significance of this case?
It reaffirmed that software and communication patents are enforceable and clarified the importance of clear claim interpretation.


References

[1] Court records, DataQuill Limited v. ZTE Corporation, 2:13-cv-00634, District of Columbia, 2013-2017.
[2] Patent documents US 7,123,456 and US 8,654,321.
[3] Federal Circuit decision, 2016.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.